IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-10-26
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, dose-escalation and cohort-expansion phase I clinical
study to evaluate the safety and tolerability, pharmacokinetics profile, efficacy and
immunogenicity of IMM2520 in subjects with advanced solid tumors.